The breast-and ovarian-specific tumor suppressor, BRCA1, has been implicated to function in many nuclear processes, including DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. Utilizing a previously described interaction between BRCA1 and RNA helicase A (RHA), we have developed a dominant-negative approach to block BRCA1 function in human breast epithelial cells. Overexpression of a truncated RHA peptide that can bind to the BRCA1 carboxy-terminus prevents normal BRCA1 function, such as BRCA1 association with nuclear foci following DNA damage. Overexpression of this dominant-negative protein induces pleomorphic nuclei, aberrant mitoses with extra centrosomes, and tetraploidy. This model system allows us to observe changes to mammary epithelial cells that occur acutely following loss of BRCA1 function. Furthermore, inhibition of BRCA1 via overexpressing the RHA fragment coincides with a reduction in PARP-1 protein expression, suggesting a possible mechanism for BRCA1 in the maintenance of genomic integrity. Oncogene (2003) 22, 983-991.
Introduction
The function of the breast-and ovarian-specific tumor suppressor, BRCA1, has been analysed in several systems. The various functions ascribed to BRCA1 include transcription (Monteiro et al., 1996; Scully et al., 1997a) , chromatin remodeling (Hu et al., 1999; Bochar et al., 2000) , cell cycle checkpoint enforcement (Larson et al., 1997; Somasundaram et al., 1997; MacLachlan et al., 2000) , various pathways of DNA repair (Gowen et al., 1998; Abbott et al., 1999; Moynahan et al., 1999; Snouwaert et al., 1999) , and centrosome replication (Xu et al., 1999; Hsu et al., 2001) .
Among these proposed activities of BRCA1, it is unclear which of these are directly dependent upon normal BRCA1 function, and which are secondary effects.
Mutation of BRCA1 results in a defect in the maintenance of genomic stability. HCC1937 cells, tumor cells of breast epithelial origin that have mutated both BRCA1 alleles, are sensitive to g-irradiation and defective for transcription-coupled repair (Abbott et al., 1999) . Studies of BRCA1-deficient mouse embryos and derived mouse cell lines reveal hypersensitivity to girradiation, numerical and structural chromosomal abnormalities, a defective G 2 /M checkpoint, aneuploidy, and defects in the processes of homologous recombination and transcription-coupled repair (Gowen et al., 1998; Shen et al., 1998; Moynahan et al., 1999; Snouwaert et al., 1999; Xu et al., 1999) . Also, BRCA1 forms nuclear foci during S phase that disperse and subsequently reform in response to DNA-damaging agents (Scully et al., 1997b) . The role of BRCA1 in genomic stability appears critical for all cell types, not just breast and ovarian epithelial cells, the progenitors of BRCA1-dependent tumors.
Experiments that alter BRCA1 expression have revealed several phenotypes. Overexpression of wildtype BRCA1 results in apoptosis following induction of GADD45 and activation of the JNK pathway (Harkin et al., 1999) . Other experiments in which the wild-type BRCA1 gene is overexpressed have resulted in slowed progression through the cell cycle, by induction of p21 or the GADD45 and GADD153 genes (Somasundaram et al., 1997; MacLachlan et al., 2000) . It is unclear if these phenotypic changes are a direct result of altered BRCA1 function. Acute inhibition of BRCA1 may permit the distinction between primary and secondary effects.
Inhibition of BRCA1 function in human breast epithelial cells would provide a model system to investigate the molecular basis for BRCA1-dependent tumorigenesis. Towards this end, we have employed a new method to block normal BRCA1 function by overexpressing a protein that binds to the carboxy terminus of BRCA1. Of the cancer-predisposing mutations in BRCA1, 90% disrupt the carboxy-terminal domain (Szabo and King, 1995) , highlighting the importance of this domain in the tumor-suppressor function of BRCA1. BRCA1 fused to the GAL4 DNA-binding domain activates transcription in vitro on promoters containing GAL4 sites (Haile and Parvin, 1999; Schlegel et al., 2000) . Overexpression of an RHA peptide containing the BRCA1-binding domain inhibits GAL4-BRCA1-dependent transcriptional activation from a GAL4 site-dependent reporter in transiently transfected HeLa cells, indicating that RHA can regulate BRCA1 function in human cells (Anderson et al., 1998) .
In this study, we inhibit the function of BRCA1 in normal mammary epithelial cells and identify the consequences of BRCA1-inhibition. We overexpress a peptide containing the BRCA1-binding domain of RHA, which lacks other functional RHA domains, in order to inhibit the normal function of endogenous BRCA1. MCF10A cells are particularly well suited for this study, since they are a near-diploid nontumorigenic human breast epithelial cell line. Although we find that this strategy does indeed inhibit BRCA1 function in both MCF10A cells and an osteosarcoma cell line, we find that only in MCF10A cells do we observe changes consistent with early lesions in breast cancer.
Results

Strategy for inhibition of BRCA1
Inhibition of endogenous BRCA1 function was achieved by overexpression of a fragment of the RHA protein that binds to the carboxy-terminus of BRCA1. Immunoprecipitation of endogenous RHA using cell lysate from U2OS cells co-precipitates endogenous BRCA1 (Figure 1a ), demonstrating that RHA and BRCA1 associate in vivo. We hypothesize that overexpression of a fragment of the RHA protein, which binds only to BRCA1 yet lacks other key domains of the RHA polypeptide, will function as a dominant-negative inhibitor of BRCA1 function (Figure 1b) . The region of RHA-containing residues 89-344 includes sequences that were parts of domains shown to bind to CBP (residues 1-250) and RNA polymerase II (residues 230-650) (Nakajima et al., 1997) . We have found that RHA residues 1-88 are sufficient to bind to CBP (unpublished observations), but the RHA protein fused to glutathione S-transferase bound to CBP and RNA polymerase II at low levels (data not shown). Thus, while this strategy is targeted to affect endogenous BRCA1 function, it may also affect CBP and polymerase activities. Arguing against a broad effect of this treatment on CBP and RNA polymerase II function, cells overexpressing the dominant-negative RHA peptide exhibited few changes in gene expression by microarray analysis (data not shown).
Human breast epithelial MCF10A cells, or U2OS osteosarcoma cells, were infected with a recombinant adenovirus that acutely expresses the dominant-negative RHA peptide (DN-RHA) or a control virus that expresses LacZ. Overexpressed DN-RHA will compete with endogenous proteins binding to the BRCA1 carboxy-terminus and thus block BRCA1 functions dependent upon this domain. MCF10A cells were infected with virus expressing LacZ or DN-RHA at a multiplicity of infection (MOI) of 350 plaque-forming units (PFU)/cell, and harvested 27 h postinfection (hpi). At 27 hpi, morphological changes in MCF10A cells are apparent (see below). At 48 hpi, for both MCF10A and U2OS cells, there was complete cell death only in those cultures that express DN-RHA. The cause of DN-RHAinduced cell death at 48 hpi remains to be determined. Immunoprecipitation of DN-RHA from 27 hpi extracts of MCF10A cells using an antibody directed against its FLAG epitope also purified BRCA1, demonstrating that DN-RHA interacts with endogenous BRCA1 (Figure 1c) . The immunoprecipitation was specific since incubation of the cell lysate with a competing FLAG peptide prevented immunoprecipitation of both DN-RHA and BRCA1.
Inhibition of BRCA1 nuclear distribution by DN-RHA Expression of DN-RHA altered the normal nuclear distribution of BRCA1 in response to DNA damage. Treatment of MCF10A cells or U2OS cells with bleomycin caused dispersal of BRCA1 nuclear foci within 1 h, with reappearance of foci containing BRCA1 after 6 h ( Figure 2 ). Viral titers used to infect MCF10A (350 PFU/cell) and U2OS (100 PFU/cell) cells were normalized according to expression of the DN-RHA polypeptide. Infection of MCF10A or U2OS cells with control virus does not significantly alter BRCA1-containing focus formation before or after DNA damage. By contrast, prior infection of MCF10A and U2OS cells with the DN-RHA virus markedly reduces reformation of BRCA1-containing nuclear foci 6 h after DNA damage in both cell lines (Figure 2 ). Since DN-RHA binds endogenous BRCA1 and changes the response of BRCA1 to DNA damage, expression of DN-RHA thus alters normal BRCA1 function and can be used to identify acute phenotypic and molecular changes associated with the loss of BRCA1 function. (Nakajima et al., 1997; Anderson et al., 1998) . Middle: Map of the dominantnegative RHA peptide (DN-RHA). DN-RHA consists of amino acid residues 89-344 of the RHA primary sequence, which includes the BRCA1-binding domain, fused to a nuclear localization sequence (NLS) and a FLAG epitope. Bottom: Schematic representation of the interaction between DN-RHA and BRCA1. BRCA1 contains two structural motifs, an N-terminal RING finger domain, which is implicated in ubiquitin ligation, and a carboxy-terminal tandem BRCT repeat, implicated in transcriptional activation and proteinprotein interactions. DN-RHA binds to the carboxy-terminal domain of BRCA1 and inhibits the transcriptional activation function. (c) Coimmunoprecipitation of DN-RHA and endogenous BRCA1. MCF10A cells were infected with the DN-RHA virus or control virus, and cells were lysed 27 hpi. DN-RHA was precipitated using an antibody directed against the FLAG epitope, in the absence or presence of a competing FLAG peptide (0.2 mg/ml). Lanes 1-3 represent 2% of input contrast, MCF10A cells exhibited a tetraploid population only in response to DN-RHA expression ( Figure  4a, b) . U2OS cells did not exhibit tetraploidy, even when a large excess of virus was used during the infection (Figure 4 and data not shown).
Overexpression of DN-RHA causes changes in nuclear morphology
Aneuploidy is often accompanied by abnormal centrosome amplification. In addition, centrosome amplification is seen in early lesions in breast cancer (Lingle et al., 2002) . We thus tested whether the inhibition of BRCA1 function by the expression of the DN-RHA was associated with centrosome amplification. Uninfected MCF10A cells, stained with DAPI to visualize DNA, showed normal interphase nuclei, and staining for g-tubulin revealed normal centrosome number ( Figure 5a , Table 1 ). All mitotic cells contained two separated centrosomes and condensed DNA (Figure 5b ). Cells infected with a control virus were similar (Table 1) . By contrast, MCF10A cells infected Table 1 ). Four centrosomes could result from a second cell cycle after a failed cell division, but we suggest that this possibility was unlikely since the timing was too rapid. In other experimental systems, the accumulation of extra centrosomes after a failed cell division required 40 h (Meraldi et al., 1999) , but we observed the extra centrosomes in a high fraction of the mitotic cells after 27 h, approximately the length of time of a single cell cycle for MCF10A cells. U2OS cells did not exhibit either feature of extra centrosomes or of abnormal mitoses. Quantitation of the morphological changes in MCF10A and U2OS cells in response to inhibition of BRCA1 is summarized in Table 1 . Interestingly, the percentage of MCF10A cells exhibiting binuclear morphology (22.8%) was roughly consistent with the aneuploid population (16.2%; Figure 4 ). Examination of BRCA1 mutant HCC1937 cells revealed many of the same features as MCF10A cells infected with the DN-RHA virus (Figure 5f-g ). HCC1937 cells are an established cell line with one BRCA1 allele containing a carboxy-terminal truncation, and the other BRCA1 allele is deleted. This cell line is also mutant for p53 and PTEN (Tomlinson et al., 1998) . Although HCC1937 cells are not directly comparable to MCF10A cells acutely overexpressing DN-RHA, a comparison of the phenotypes supports the notion that the DN-RHA expression inhibits BRCA1 function. HCC1937 cells contain enlarged nuclei, indicative of increased DNA content, numerous centrosomes, and are binuclear. The karyotype of HCC1937 cells indicates that the cells are approximately tetraploid (Tomlinson et al., 1998) . The exaggerated morphological features of HCC1937 cells (Table 2) were strikingly similar to the phenotype of MCF10A cells with BRCA1 inhibited by DN-RHA expression. Since these features were apparent within 27 hpi in MCF10A cells, binuclear morphology, aberrant centrosome amplification, and tetraploidy represented the acute changes that occur upon loss of BRCA1 function.
PARP-1 expression is decreased in DN-RHA expressing mammary cells
The phenotype that results from inhibition of BRCA1 function in MCF10A cells was reminiscent of cells that lack poly(ADP-ribose) polymerase (PARP-1). PARP-1 catalyzes the reversible (ADP-ribosyl)ation of nuclear proteins such as histones, DNA polymerase a and b, PCNA, p53, and automodification of PARP-1 (D'Amours et al., 1999). The enzymatic activity is stimulated upon binding to a single-strand or doublestrand DNA breaks (Ohgushi et al., 1980; Benjamin and Gill, 1980) . PARP À/À mouse fibroblasts exhibit abnormal nuclear morphology and tetraploidy (SimbulanRosenthal et al., 1999 (SimbulanRosenthal et al., , 2000 . We examined PARP-1 mRNA and protein expression in Inhibition of BRCA1 by a dominant-negative RHA BP Schlegel et al levels dropped by an average of 50% in three experiments in response to DN-RHA expression, when normalized to GAPDH mRNA (Figure 6a ). PARP-1 protein levels decrease much more dramatically (Figure 6b ), indicating that BRCA1 regulates PARP-1 expression at both the transcript and the protein level.
As an internal control, caspase 3 levels were unaffected by DN-RHA expression. The absence of an 89 kDa PARP-1 proteolytic fragment indicated that the drop in PARP-1 protein was not due to caspase cleavage of the full-length 113 kDa protein, one of the initial events of apoptosis (Lazebnik et al., 1994) . There was no change in the expression of PARP-1 in U2OS cells, suggesting that BRCA1 regulation of PARP-1 expression may be cell type-specific.
Discussion
We have exploited the interaction between the BRCA1 carboxy-terminus and RHA to develop a dominantnegative approach, which acutely inhibits BRCA1 function in human breast epithelial cells. This approach permits the evaluation of changes in phenotype that occur soon after loss of BRCA1 function. Overexpression of the DN-RHA peptide elicited a host of phenotypic changes in MCF10A cells consistent with the proposed role of BRCA1 function in the maintenance of genomic stability. These changes include a failure of BRCA1 foci to reform after DNA damage, binuclear morphology, tetraploidy, and abnormal centrosome amplification. We examined a BRCA1-deficient cell line, HCC1937, and discovered similar abnormalities in nuclear morphology and centrosome number, suggesting that loss of BRCA1 function is directly responsible for this phenotype. It was previously unknown that the centrosome number is abnormal in these cells. Prior studies have demonstrated that BRCA1-deficient cells, derived from knockout mouse embryos, develop aneuploidy and extra centrosomes, but this phenotype is evaluated after many days of growth (Shen et al., 1998; Xu et al., 1999) . Our ability to induce centrosome expansion within 27 h by acute overexpression of a dominant-negative inhibitor of BRCA1 function suggests that BRCA1 directly regulates the pathway controlling centrosome replication. Overexpression of DN-RHA may relieve this inhibitory function. Perhaps some cell types, such as U2OS cells, may have a second pathway regulating centrosome replication independent of BRCA1, so that centrosome replication remains normal. BRCA1 has been found to associate with centrosomes in mitotic cells (Hsu and White, 1998; Hsu et al., 2001 ). An internal domain of BRCA1, amino acid residues 504-803, binds directly to g-tubulin, and overexpression of this domain results in centrosome expansion in stably transfected COS-7 cells (Hsu et al., 2001) .
A comparison of our results with other experimental results in which BRCA1 was inhibited is illustrative. In experiments in which the isolated carboxy-terminus of BRCA1 was overexpressed, the G2-M cell cycle checkpoint was defective (Larson et al., 1997) . In one set of experiments the BRCA1 concentration was reduced in HBL100 cells using a BRCA1-specific ribozyme. Ribozyme-treated cells were sensitive to DNA-damaging agents and resistant to microtubule- interfering agents (Lafarge et al., 2001) . When the gtubulin-binding domain of BRCA1 was stably overexpressed in COS-7 cells, cell death with abnormal centrosome amplification was observed (Hsu et al., 2001) . In our experiments, we also observed abnormal mitoses and centrosome accumulation, suggesting that BRCA1 function is important in these processes. The common thread among these four different approaches toward inhibition of BRCA1 function lends support to a role for BRCA1 in the regulation of centrosome replication and mitosis. Our study further adds the important insight that while BRCA1 nuclear dot redistribution was inhibited by DN-RHA in both the U2OS and MCF10A cells, only in the MCF10A cells were the mitotic phenotypes apparent. This observation suggests that the effects of BRCA1 may be cell type-specific, and this is consistent with BRCA1 being a breast cancer-specific tumor suppressor. Inhibition of BRCA1 in MCF10A cells results in a striking decrease in PARP-1 protein expression, raising the possibility that many of the observed phenotypic changes may actually be caused by loss of PARP-1. The similarities between BRCA1 and PARPdeficient mouse cells are remarkable. Both BRCA1-and PARP-deficient cells exhibit abnormal nuclear morphology, tetraploidy, and hypersensitivity to g-irradiation (Wang et al., 1995 (Wang et al., , 1997 de Murcia et al., 1997; Simbulan-Rosenthal et al., 1999 . The observation of chromatid breaks and quadriradial chromosomes (Shen et al., 1998; Xu et al., 1999) has implicated BRCA1 in sister chromatid exchange (SCE), a form of homologous recombination (Sonoda et al., 1999) . PARP-deficient mouse fibroblasts exhibit elevated levels of SCEs (de Murcia et al., 1997; Wang et al., 1997) , suggesting that BRCA1 and PARP-1 regulate the fidelity of SCE. Also, PARP-1 functions as a transcriptional coactivator (Meisterernst et al., 1997) , inhibits transcription during DNA damage (Taniguchi et al., 1982) , and enhances transcript elongation (Vispe et al., 2000) , consistent with the observed transcriptioncoupled repair defect in BRCA1-deficient mouse embryonic stem cells (Abbott et al., 1999; Gowen et al., 1998) and with the transcription function of BRCA1 (Haile and Parvin, 1999; Schlegel et al., 2000) . However, acute loss of PARP-1 expression is not sufficient to account for all roles attributed to BRCA1. Unlike BRCA1 knockouts, PARP-deficient mice are viable (Wang et al., 1995; de Murcia et al., 1997) . Nonetheless, identification of PARP-1 as a potential downstream effector of BRCA1 function in the maintenance of genomic stability represents substantial progress in our understanding of the tumor-suppressor function of BRCA1.
Materials and methods
Protein expression and immunoprecipitation A recombinant adenovirus expressing a dominant-negative inhibitor of BRCA1 function was generated using the Adeno-Quest expression system (Quantum Biotechnologies, Inc.). Virus titer was determined by serial dilution using a standard plaque formation assay. Infected cells were lysed in buffer containing 50 mm Tris, pH 7.9, 150 mm NaCl, 1% Nonidet P-40, 5 mm EDTA, and 0.25% protease inhibitor cocktail (Sigma). Supernatant was analysed directly (40 mg) or was incubated overnight at 41C with M2 agarose (Sigma) or an RHA-directed antibody bound to protein G sepharose (Pharmacia Biotech). Samples were washed with lysis buffer (0.1% NP-40) and resolved by SDS-PAGE, transferred to nitrocellulose, probed with specific antibody and visualized by chemiluminescence.
Fluorescence microscopy Cells were grown on glass cover slips, fixed and permeabilized as previously described (Scully et al., 1997b) and washed three times with PBS. Samples were then incubated for 1 h at 371C with a rabbit polyclonal antibody directed against BRCA1. Samples were washed three times with PBS, and incubated for 1 h at room temperature with a 1 : 100 dilution of a TRITC-conjugated goat anti-rabbit secondary antibody (Sigma). Samples were washed five times with PBS, and then mounted on glass slides with a mounting media containing DAPI (Vectashield). Samples were viewed at Â 1000 magnification using an Axioskop upright microscope (Carl Zeiss) and images were captured using a model 2.3.1 SPOT digital camera (Diagnostic Instruments, Inc.). For centrosome localization, cells were fixed in methanol followed by acetone for 10 min at À201C. Staining was performed overnight at room temperature using a 1 : 1000 dilution of an antibody directed against g-tubulin (Sigma). All incubations were performed in PBS containing 4% goat serum. Some fluorescent microscopy images were obtained using a Bio-Rad Radiance 2000 confocal and laser scanning microscope enhanced by a Ti Sapphire Tsunami laser from SpectraPhysics.
Flow cytometry Cells were trypsinized and then washed in PBS containing 1% BSA, fixed overnight in 70% ethanol, incubated with RNAse A (100 mg/ml) and stained for 1 h with propidium iodide (50 mg/ml), and then analysed for DNA content using a Beckman Coulter EPICS XL-MCL flow cytometer. G 2 /M cells and tetraploid cells were discriminated from cell doublets using the pulse-width/pulse-area signal ratio. Data were analysed using the Multicycle software package (Phoenix Flow Systems).
Northern analysis mRNA was purified using the FastTrack 2.0 kit. (Invitrogen). Samples were resolved by denaturing agarose gel electrophoresis, transferred to a nylon membrane, and hybridized to probe according to standard protocols. Signals were quantified using a PhosphorImager (Molecular Dynamics).
